DERENZINI, ENRICO
DERENZINI, ENRICO
Dipartimento di Scienze della Salute
A 3-gene signature based on MYC, BCL-2 and NFKBIA improves risk stratification in diffuse large B-cell lymphoma
2020 E. Derenzini, S. Mazzara, F. Melle, G. Motta, M. Fabbri, R. Bruna, C. Agostinelli, A. Cesano, C.A. Corsini, N. Chen, S. Righi, E. Sabattini, A. Chiappella, A. Calleri, S. Fiori, V. Tabanelli, A. Cabras, G. Pruneri, U. Vitolo, A.M. Gianni, A. Rambaldi, P. Corradini, P.L. Zinzani, C. Tarella, S. Pileri
A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma
2008 P.L. Zinzani, M. Tani, S. Fanti, V. Stefoni, G. Musuraca, U. Vitolo, A. Perrotti, M. Fina, E. Derenzini, M. Baccarani
A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma
2011 G. Brandi, G. Biasco, M.G. Mirarchi, R. Golfieri, A. Di Paolo, A. Borghi, S. Fanello, E. Derenzini, V. Agostini, E. Giampalma, A. Cappelli, P. Pini, S. Costantini, R. Danesi, L. Bolondi, F. Piscaglia
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
2008 P.L. Zinzani, M. Tani, S. Fanti, V. Stefoni, G. Musuraca, P. Castellucci, E. Marchi, M. Farsad, M. Fina, C. Pellegrini, L. Alinari, E. Derenzini, A. de Vivo, F. Bacci, S. Pileri, M. Baccarani
A phase ii trial of short course fludarabine, mitoxantrone, rituximab followed by 90y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma
2012 P.L. Zinzani, M. Tani, A. Pulsoni, A. De Renzo, V. Stefoni, A. Broccoli, G.C. Montini, M. Fina, C. Pellegrini, L. Gandolfi, E. Cavalieri, F. Torelli, F. Scopinaro, L. Argnani, F. Quirini, E. Derenzini, M. Rossi, S. Pileri, S. Fanti, M. Baccarani
Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases
2013 G. Brandi, E. Derenzini, A. Falcone, G. Masi, F. Loupakis, A. Pietrabissa, A.D. Pinna, G. Ercolani, M.A. Pantaleo, S. Di Girolamo, G.L. Grazi, F. De Rosa, G. Biasco
Allotransplant in relapsed or refractory aggressive T-cell lymphomas: Retrospective monocentric analysis of 14 patients
2013 A. Broccoli, M. Stanzani, G. Bandini, F. Bonifazi, V. Stefoni, C. Pellegrini, E. Derenzini, L. Gandolfi, F. Quirini, L. Argnani, M. Tschon, B. Casadei, M. Baccarani, P.L. Zinzani
An integrated prognostic model for diffuse large B-cell lymphoma treated with immunochemotherapy
2022 M. Rodríguez, R. Alonso-Alonso, I. Fernández-Miranda, R. Mondéjar, L. Cereceda, Á. Tráscasa, A. Antonio-Da Conceiçao, J. Borregón, L. Gato, L. Tomás-Roca, C. Bárcena, B. Iglesias, F. Climent, E. González-Barca, F.I. Camacho, É. Mayordomo, G. Olmedilla, P. Gómez-Prieto, Y. Castro, J. Serrano-López, J. Sánchez-García, S. Montes-Moreno, M. García-Cosío, P. Martín-Acosta, J.F. García, M. Planelles, C. Quero, M. Provencio, I. Mahíllo-Fernández, S.M. Rodríguez-Pinilla, E. Derenzini, S. Pileri, M. Sánchez-Beato, R. Córdoba, M.A. Piris
An isolated penile mass in a young adult turned out to be a primary marginal zone lymphoma of the penis : a case report and a review of literature
2013 G. Gentile, A. Broccoli, E. Brunocilla, R. Schiavina, M. Borghesi, D. Romagnoli, L. Bianchi, E. Derenzini, C. Agostinelli, A. Franceschelli, F. Colombo, P.L. Zinzani
Association of essential thrombocythemia and non-Hodgkin lymphoma: A single-centre experience
2009 F. Palandri, E. Derenzini, E. Ottaviani, N. Polverelli, L. Catani, F. Salmi, E. Sabattini, F. Bacci, P.L. Zinzani, M. Baccarani, N. Vianelli
Bendamustine efficacy in Hodgkin lymphoma patients relapsed/refractory to brentuximab vedotin
2013 P.L. Zinzani, E. Derenzini, C. Pellegrini, M. Celli, A. Broccoli, L. Argnani
Bendamustine: Role and evidence in lymphoma therapy, an overview
2014 E. Derenzini, P.L. Zinzani, B.D. Cheson
BET Inhibition-Induced GSK3β Feedback Enhances Lymphoma Vulnerability to PI3K Inhibitors
2018 E. Derenzini, P. Mondello, T. Erazo, A. Portelinha, Y. Liu, M. Scallion, Z. Asgari, J. Philip, P. Hilden, D. Valli, A. Rossi, H. Djaballah, O. Ouerfelli, E. de Stanchina, V.E. Seshan, R.C. Hendrickson, A. Younes
Blastic plasmacytoid dendritic cell neoplasm : State of the art and prospects
2019 M.R. Sapienza, A. Pileri, E. Derenzini, F. Melle, G. Motta, S. Fiori, A. Calleri, N. Pimpinelli, V. Tabanelli, S. Pileri
Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: A multicenter retrospective study
2013 P.L. Zinzani, C. Pellegrini, E. Merla, F. Ballerini, A. Fabbri, A. Guarini, V. Pavone, G. Quintini, B. Puccini, M.L. Vigliotti, V. Stefoni, E. Derenzini, A. Broccoli, L. Gandolfi, F. Quirini, B. Casadei, L. Argnani, M. Baccarani
Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma : the Italian experience and results of its use in daily clinical practice outside clinical trials
2013 P.L. Zinzani, S. Viviani, A. Anastasia, U. Vitolo, S. Luminari, F. Zaja, P. Corradini, M. Spina, E. Brusamolino, A.M. Gianni, A. Santoro, B. Botto, E. Derenzini, C. Pellegrini, L. Argnani
Bronchus-associated lymphoid tissue lymphomas : an update of a rare extranodal maltoma
2007 P.L. Zinzani, V. Poletti, M. Zompatori, M. Tani, L. Spaggiari, S. Tomassetti, A. Broccoli, E. Derenzini, M. Baccarani
Characterization of a c-Rel inhibitor that mediates anticancer properties in hematologic malignancies by blocking NF-κB-controlled oxidative stress responses
2016 Y. Shono, A.Z. Tuckett, H.-. Liou, E. Doubrovina, E. Derenzini, S. Ouk, J.J. Tsai, O.M. Smith, E.R. Levy, F.M. Kreines, C.G.K. Ziegler, M.I. Scallion, M. Doubrovin, G. Heller, A. Younes, R.J. O'Reilly, M.R.M. Van Den Brink, J.L. Zakrzewski
Chemotherapy after PD-1 inhibitors in relapsed/refractory Hodgkin lymphoma: Outcomes and clonal evolution dynamics
2022 E. Calabretta, A. Guidetti, F. Ricci, M. Di Trani, C. Monfrini, M. Magagnoli, S. Bramanti, D. Maspero, L. Morello, M. Merli, A. Di Rocco, A. Graudenzi, E. Derenzini, M. Antoniotti, D. Rossi, P. Corradini, A. Santoro, C. Carlo-Stella
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
2020 F. Passamonti, C. Cattaneo, L. Arcaini, R. Bruna, M. Cavo, F. Merli, E. Angelucci, M. Krampera, R. Cairoli, M.G. Della Porta, N. Fracchiolla, M. Ladetto, C. Gambacorti Passerini, M. Salvini, M. Marchetti, R. Lemoli, A. Molteni, A. Busca, A. Cuneo, A. Romano, N. Giuliani, S. Galimberti, A. Corso, A. Morotti, B. Falini, A. Billio, F. Gherlinzoni, G. Visani, M.C. Tisi, A. Tafuri, P. Tosi, F. Lanza, M. Massaia, M. Turrini, F. Ferrara, C. Gurrieri, D. Vallisa, M. Martelli, E. Derenzini, A. Guarini, A. Conconi, A. Cuccaro, L. Cudillo, D. Russo, F. Ciambelli, A.M. Scattolin, M. Luppi, C. Selleri, E. Ortu La Barbera, C. Ferrandina, N. Di Renzo, A. Olivieri, M. Bocchia, M. Gentile, F. Marchesi, P. Musto, A.B. Federici, A. Candoni, A. Venditti, C. Fava, A. Pinto, P. Galieni, L. Rigacci, D. Armiento, F. Pane, M. Oberti, P. Zappasodi, C. Visco, M. Franchi, P.A. Grossi, L. Bertu, G. Corrao, L. Pagano, P. Corradini